These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 18277959

  • 1. Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome.
    Slovin SF.
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):972-80. PubMed ID: 18277959
    [Abstract] [Full Text] [Related]

  • 2. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 4. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF.
    Cancer J; 2008 Aug; 14(1):26-34. PubMed ID: 18303480
    [Abstract] [Full Text] [Related]

  • 5. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
    Immunol Lett; 2007 Nov 15; 113(2):90-8. PubMed ID: 17913245
    [Abstract] [Full Text] [Related]

  • 6. Prostate cancer immunotherapy.
    McNeel DG.
    Curr Opin Urol; 2007 May 15; 17(3):175-81. PubMed ID: 17414515
    [Abstract] [Full Text] [Related]

  • 7. Immunologic targeting: how to channel a minimal response for maximal outcome.
    Slovin SF.
    Curr Opin Urol; 2006 May 15; 16(3):179-85. PubMed ID: 16679856
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunotherapeutics in development for prostate cancer.
    Harzstark AL, Small EJ.
    Oncologist; 2009 Apr 15; 14(4):391-8. PubMed ID: 19342474
    [Abstract] [Full Text] [Related]

  • 10. The immunotherapy of prostate and bladder cancer.
    Totterman TH, Loskog A, Essand M.
    BJU Int; 2005 Oct 15; 96(5):728-35. PubMed ID: 16144528
    [Abstract] [Full Text] [Related]

  • 11. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC, Arredouani MS, Hollenbeck B, Eng MH, Rubin MA, Sanda MG.
    Prostate; 2008 May 15; 68(7):715-27. PubMed ID: 18302222
    [Abstract] [Full Text] [Related]

  • 12. Rational peptide-based tumour vaccine development and T cell monitoring.
    Scheibenbogen C, Letsch A, Schmittel A, Asemissen AM, Thiel E, Keilholz U.
    Semin Cancer Biol; 2003 Dec 15; 13(6):423-9. PubMed ID: 15001161
    [Abstract] [Full Text] [Related]

  • 13. DC therapy for prostate cancer.
    Swindle PW, Tepes S, Clements J.
    Cytotherapy; 2004 Dec 15; 6(2):164-71. PubMed ID: 15203993
    [Abstract] [Full Text] [Related]

  • 14. Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?
    Slovin SF.
    Expert Rev Anticancer Ther; 2008 Mar 15; 8(3):465-74. PubMed ID: 18366293
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer vaccines: current status.
    Hwang LC, Fein S, Levitsky H, Nelson WG.
    Semin Oncol; 1999 Apr 15; 26(2):192-201. PubMed ID: 10597730
    [Abstract] [Full Text] [Related]

  • 16. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ, Lee DI.
    Urol Oncol; 2008 Apr 15; 26(6):576-80. PubMed ID: 18996314
    [Abstract] [Full Text] [Related]

  • 17. [Vaccine therapy of prostate cancer].
    Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D.
    Aktuelle Urol; 2005 Sep 15; 36(5):407-16. PubMed ID: 16163603
    [Abstract] [Full Text] [Related]

  • 18. DNA vaccines for the treatment of prostate cancer.
    Alam S, McNeel DG.
    Expert Rev Vaccines; 2010 Jul 15; 9(7):731-45. PubMed ID: 20624047
    [Abstract] [Full Text] [Related]

  • 19. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF, Drake CG.
    Surg Oncol Clin N Am; 2007 Oct 15; 16(4):861-71, x. PubMed ID: 18022549
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 15; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.